Join to View Full Profile
8517 Oakmont LnIndianapolis, IN 46260
Phone+1 317-251-6092
Join Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our "call shielding" and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
You already have 13 invites waiting! - Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Neil Bodick, MD is a family physician in Indianapolis, Indiana. He is currently licensed to practice medicine in Indiana and Pennsylvania.
Education & Training
Albert Einstein College of MedicineClass of 1983
Certifications & Licensure
IN State Medical License 1993 - 2025
PA State Medical License 1984 - 1992
Clinical Trials
- Study to Characterize the PK and Local Extent and Duration of Exposure From FX006 in Patients With OA of the Knee Start of enrollment: 2015 Nov 01
- Study to Compare Exposure of TA Following Administration of Either FX006 or TAcs in Patients With Bilateral Knee OA Start of enrollment: 2017 Dec 06
- Study to Compare Exposure of TA Following Administration of FX006 or TAcs in Patients With OA of the Shoulder or Hip Start of enrollment: 2017 Dec 18
Publications & Presentations
PubMed
- 8 citationsEfficacy and Safety of FX201, a Novel Intra-Articular IL-1Ra Gene Therapy for Osteoarthritis Treatment, in a Rat Model.Rebecca Senter, Rogely Boyce, Marko Repic, Emily Walsh Martin, Monika Chabicovsky
Human Gene Therapy. 2022-05-01 - 74 citationsMachine-learning, MRI bone shape and important clinical outcomes in osteoarthritis: data from the Osteoarthritis Initiative.Michael A. Bowes, Katherine Kacena, O A Alabas, Alan Brett, B. Dube
Annals of the Rheumatic Diseases. 2021-04-01 - 21 citationsTriamcinolone acetonide extended-release in patients with osteoarthritis and type 2 diabetes: a randomized, phase 2 study.Steven Russell, Robert Sala, Philip G. Conaghan, George Habib, Quang Vo
Rheumatology. 2018-12-01
Press Mentions
Dr. Mike Clayman, CEO of Flexion Therapeutics, on Developing New Therapies for Musculoskeletal DisordersJune 8th, 2021
